Somatostatin Analogs Market revenue to reach USD 10 Billion by 2035, says Research Nester
16 oct. 2023 05h30 HE
|
Research Nester
New York, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The global somatostatin analogs market size is slated to expand at ~6% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 10...
Somatostatin Analogs Market revenue to reach USD 10 Billion by 2035, says Research Nester
03 oct. 2023 07h00 HE
|
Research Nester
New York, Oct. 03, 2023 (GLOBE NEWSWIRE) -- The global somatostatin analogs market size is predicted to expand at ~ 6% CAGR between 2023 and 2035. The market is projected to garner a revenue of USD...
Propulsion of Neuroendocrine Tumors Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
29 mai 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, May 29, 2023 (GLOBE NEWSWIRE) -- Propulsion of Neuroendocrine Tumors Pipeline as Novel and Extensive 60+ Therapies Likely to Enter in the Treatment Domain | DelveInsight The...
ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022
06 sept. 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...
ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress
15 juin 2022 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, June 15, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will host an industry-sponsored lunch symposium on...
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
19 avr. 2022 01h00 HE
|
Curium
ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market. Curium will now...
Provectus Biopharmaceuticals Announces Oral Presentation of Updated Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference
16 mars 2022 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium)...
Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan
28 févr. 2022 06h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO and NAGOYA, Japan, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and...
Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers
03 janv. 2022 11h00 HE
|
RadioMedix Inc.
Houston, TX and Plano, TX, Jan. 03, 2022 (GLOBE NEWSWIRE) -- RadioMedix and Orano Med are pleased to announce the initiation of the Phase II clinical trial of AlphaMedix™ with the treatment of the...
RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY
18 nov. 2021 17h00 HE
|
RadioMedix Inc.
Houston, TX, Nov. 18, 2021 (GLOBE NEWSWIRE) -- RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Direct to Phase II...